Atlas Trials

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Clinical trial NCT05031780 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05031780
Sponsor
Agios Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Sickle Cell Disease
Start date
2022-02-11
Primary completion
2025-10-30
Enrollment
286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.